Avantor, Inc.
AVTRHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Avantor, Inc. focuses on Medical Instruments & Supplies services and products. Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the. Valued at $11.69B, AVTR is a large-cap name in its sector. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips.
Market Cap
$11.69B
Beta
0.94
P/E (TTM)
—
P/E (Fwd)
19.75
EPS (TTM)
$-0.83
EPS (Fwd)
$0.88
ROE
-9.7%
ROA
2.7%
Cash
$306.8M
Total Debt
$3.70B
Free CF
$450.3M
52W Change
14.4%
Annual Financials
Cash vs Debt
Where AVTR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AVTR finished 45.45% above its 150-day moving average ($11.20) and 48.36% above its 200-day moving average ($10.98). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AVTR overbought or oversold?
At the October 20, 2026 close, AVTR's RSI(14) was 67.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, AVTR has $306.8M in cash with $3.70B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $450.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -9.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.7% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $7.51B (2022) to $6.55B (2025), a 13% decline worth watching.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing AVTR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.